Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bagust

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Health Technology Assessment (Winchester, England)|December 14, 2011
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysisN Fleeman, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|May 29, 2010
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary interventionJ Greenhalgh, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|January 18, 2006
The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviewsC Black, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|September 14, 2004
Coronary artery stents: a rapid systematic review and economic evaluationR Hill, A Bagust, A Bakhai, et al.
Health Technology Assessment (Winchester, England)|May 29, 2010
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancerN Fleeman, A Bagust, C McLeod, et al.
Health Technology Assessment (Winchester, England)|July 2, 2009
Erlotinib for the treatment of relapsed non-small cell lung cancerC McLeod, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|November 5, 2010
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancerJ Greenhalgh, C McLeod, A Bagust, et al.
Health Technology Assessment (Winchester, England)|June 11, 2015
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluationT Brown, G Pilkington, A Bagust, et al.
Health Technology Assessment (Winchester, England)|July 27, 2013
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluationT Brown, G Pilkington, A Bagust, et al.
Health Technology Assessment (Winchester, England)|December 11, 2008
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluationC McLeod, N Fleeman, J Kirkham, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Health Technology Assessment (Winchester, England)|December 14, 2011
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysisN Fleeman, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|May 29, 2010
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary interventionJ Greenhalgh, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|January 18, 2006
The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviewsC Black, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|September 14, 2004
Coronary artery stents: a rapid systematic review and economic evaluationR Hill, A Bagust, A Bakhai, et al.
Health Technology Assessment (Winchester, England)|May 29, 2010
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancerN Fleeman, A Bagust, C McLeod, et al.
Health Technology Assessment (Winchester, England)|July 2, 2009
Erlotinib for the treatment of relapsed non-small cell lung cancerC McLeod, A Bagust, A Boland, et al.
Health Technology Assessment (Winchester, England)|November 5, 2010
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancerJ Greenhalgh, C McLeod, A Bagust, et al.
Health Technology Assessment (Winchester, England)|June 11, 2015
Corrigendum: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluationT Brown, G Pilkington, A Bagust, et al.
Health Technology Assessment (Winchester, England)|July 27, 2013
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluationT Brown, G Pilkington, A Bagust, et al.
Health Technology Assessment (Winchester, England)|December 11, 2008
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluationC McLeod, N Fleeman, J Kirkham, et al.
Pageof 6